Epitomics Plans Taiwan IPO Later in 2011

Epitomics, the San Francisco-area biopharma with two major facilities in China, intends to IPO on the Taiwan Stock Exchange before the end of the year. Epitomics’ business model is based on the company’s proprietary RabMAb® monoclonal antibody technology, which the company says provides better antigen recognition than the more common mouse models. Because the company is still awaiting approval from the Taiwan Stock Exchange for the IPO, the company has not released details of the transaction. More details.... Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});